<DOC>
	<DOCNO>NCT00910000</DOCNO>
	<brief_summary>This trial Phase Ib/II study carboplatin/gemcitabine/vorinostat treatment platinum sensitive recurrent ovarian cancer . The carboplatin gemcitabine combination FDA approve regimen platinum-sensitive recurrent ovarian cancer . Vorinostat type drug call histone deacetylase inhibitor ( HDAC inhibitor ) . HDAC inhibitor interact chromosome cancer cell cause cancer cell stop grow . Vorinostat show decrease amount ovarian cancer cell grow laboratory also may enhance anti-cancer effect carboplatin.The purpose Phase Ib study determine high dose drug vorinostat give safely combination carboplatin gemcitabine . Not everyone participate research study receive dose study drug , vorinostat , carboplatin gemcitabine dos hold constant . Vorinostat dose depend previous enrollment tolerability . The expansion Phase II study use vorinostat dose found Phase Ib study combination carboplatin/gemcitabine single agent maintenance therapy well understand toxicity efficacy .</brief_summary>
	<brief_title>Vorinostat , Carboplatin Gemcitabine Women With Recurrent , Platinum-Sensitive Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary Phase Ib : Determine maximally tolerate dose ( MTD ) vorinostat use combination standard ( fix ) dose carboplatin/gemcitabine 21 day cycle patient recurrent platinum-sensitive ovarian cancer Phase II : Estimate median progression-free survival ( PFS ) patient treat carboplatin/gemcitabine/vorinostat vorinostat maintenance Secondary - Estimate response rate carboplatin/gemcitabine/vorinostat - Assess toxicity carboplatin/gemcitabine/vorinostat - Assess toxicity maintenance vorinostat - Measure overall survival ( OS ) progression-free survival ( PFS ) STATISTICAL DESIGN : The Phase Ib study originally design follow standard 3+3 dose escalation design evaluate 4 vorinostat dose levels.The DLT observation period 21-day cycle 1 length . Note : Ultimately 6 dose level evaluate protocol amend add dose level , de-escalating cumulative vorinostat dose per cycle 2 3 participant dose level cohort 2A , 1B 1C experienced DLTs . In Phase II study , median PFS 13 month would worthy study , represent 66 % improvement compare historical median 8.6 month observe carboplatin/gemcitabine . With 36 evaluable patient , 80 % power reject null hypothesis favor alternative 5 % significance level .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm recurrent epithelial ovarian cancer , fallopian tube cancer , peritoneal cancer Must receive platinumbased chemotherapy regimen initial diagnosis Patients primary platinumsensitive ( defined cancer initially platinumsensitive follow progressionfree interval first exposure platinum 6 month great ) recurrent ovarian , tubal peritoneal cancer Must elevate CA125 ( twice ULN ) within 2 week enrol study ( 2 pretreatment measurement twice upper limit institutional normal drawn least 1 day 14 day apart ) . At least one sample check within one week start treatment . Measurable cancer via RECIST criterion via CT MRI scan require clinically indicate monitor . For patient elevate CA125 ( twice ULN ) , participant must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) 20mm great conventional technique 10mm great spiral CT scan . 18 year age old Life expectancy great 16 week ECOG Performance Status 0 , 1 , 2 Participants must normal organ marrow function outline protocol Patients could receive 1 prior nonplatinum chemotherapy regimen recurrent set ( antiangiogenic agent phase II nonhormonal therapy use treat recurrent cancer count prior nonplatinum therapy ) one prior platinum ( use treat initial diagnosis ) . Patients may receive 2 prior hormonal therapy . Women childbearing potential must agree use adequate contraception prior study entry duration study participation Must able willing take oral medication No clinical radiographic evidence exist impend bowel obstruction Should least 2 week surgical procedure , exception minor surgery , port placement Patients know carboplatin hypersensitivity reaction receive carboplatin follow allergist , follow publish hypersensitivity desensitization protocol receive carboplatin , agree receive carboplatin circumstance Patients take valproic acid epilepsy may enroll discontinue valproic acid 30 day prior enrol washout Patients must normal QTc interval history QTc prolongation EKG Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier May receive investigational agent Participants know brain metastasis exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition vorinostat Uncontrolled intercurrent illness include , limited ongoing active infection , pulmonary disease , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant breastfeed woman Individuals history different malignancy ineligible except follow circumstance : diseasefree least 5 year deem investigator low risk recurrence malignancy ; cervical cancer situ , concurrent stage IA grade I endometrial cancer , basal cell squamous cell carcinoma skin Patients take valproic acid unless valproic acid stop least 30 day prior enrollment Receipt past HDAC inhibitor treatment malignancy Receipt radiation therapy &gt; 25 % bone marrowbearing area Patients gastrointestinal disorder likely interfere absorption vorinostat Known active HIV hepatitis viral infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>carboplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>vorinostat</keyword>
</DOC>